Evaluation of safety profile of ChAdOx1-nCoV-19 Coronavirus (Covisheild) Vaccine among health care professionals in a tertiary care hospital: 6 months follow-up observation

ABSTRACT

Materials and Methods: This is 6 months follow-up observation of vaccinated individuals, 545 health care workers have taken Covishield Vaccine for a duration of 1 month in a tertiary care hospital in two doses with 28 days apart. ChAdOx1-nCoV-19 Coronavirus (Covishield) Vaccine;Health Care Professionals;Adverse Reactions INTRODUCTION Coronavirus disease 2019 (COVID-19) infection initially emerged in Wuhan city, China, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing various manifestations mainly respiratory illness ranging from mild to moderate disease (80%) to severe disease (15%), and even critical illness (5%) with high case fatality rate of around 0.5-2.8. Few side effects, particularly rare and very rare onews that are seen in real uncontrolled environment may not be evident. [...]it is necessary to closely monitor the safety and effectiveness of approved vaccines in the market. [7,8] Hence, the Pharmacovigilance committee of a tertiary care hospital followed up the vaccinated individuals for half a year to check for the safety of Covishield vaccine and severity of adverse effects.